Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Innovative Medicines Initiative Resource Report Resource Website 100+ mentions |
Innovative Medicines Initiative (RRID:SCR_003754) | IMI | organization | Initiative to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by initiating and managing consortia composed of the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organizations, and medicines regulators. IMI is a public-private partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA), with a timeframe separated into two phases (2008-2013, 2014-2024) that are each defined by unique research agendas. The first phase (2008 2013) had four pillars that defined the focus of its research agenda: * Predicting safety: evaluating the safety of a compound during the pre-clinical phase of the development process and the later phases in clinical development. * Predicting efficacy: improving the ability to predict how a drug will interact in humans and how it may produce a change in function. * Knowledge management: utilization of information and data for predicting safety and efficacy. * Education and training: closing existing training gaps in the drug development process. Some of the consortia managed under IMI focused on specific health issues while others focused on broader challenges in drug development. Additionally, IMI launched a number of education and training projects during its first phases. The goal of the second phase (IMI2, 2014-2024) is to develop next generation vaccines and drugs. The focus is on delivering the right prevention and treatment for the right patient at the right time. There is a strong focus on the development of new medicines with an emphasis on tools and methods that accelerate patient access to new medicines. IMI2's agenda can be defined by four axes of research: * target validation and biomarker research (efficacy and safety) * adoption of innovative clinical trial paradigms * innovative medicines * patient-tailored adherence programs As part of its distinct goals, IMI2 aims to deliver: * 30% better success rate in clinical trials of priority medicines identified by the WHO; clinical proof of concept in immunological, respiratory, neurological and neurodegenerative diseases in five years; * new and approved diagnostic markers for four of these diseases and at least two new medicines which could either be new antibiotics or new therapies for Alzheimer's disease. | drug development, drug, tool development, biomarker, data sharing, target validation, safety, efficacy, clinical trial, medicine, adherence program, vaccine, consortium, diagnostic marker, oncology, drug discovery |
is listed by: Consortia-pedia is related to: AddNeuroMed is related to: European Federation of Pharmaceutical Industries and Associations has parent organization: European Union has parent organization: European Federation of Pharmaceutical Industries and Associations is parent organization of: AddNeuroMed |
European Union FP7 ; Horizon 2020 ; EFPIA ; Other life science industries or organizations |
Wikidata: Q1664196, nlx_157984, grid.454814.8, ISNI: 0000 0004 0577 0821 | https://ror.org/019af4n30 | SCR_003754 | 2026-02-07 02:06:26 | 264 | |||||||
|
Global Health Innovative Technology Fund Resource Report Resource Website 10+ mentions |
Global Health Innovative Technology Fund (RRID:SCR_003753) | GHIT Fund, GHIT | institution | A consortium that focuses their efforts on discovering and developing new pharmaceutical drugs, vaccines (both preventive and therapeutic) and diagnostics against the infectious diseases that are prevalent in developing countries. The initial targets are those disorders designated by WHO as neglected tropical diseases prevalent in developing nations. The consortium aims to facilitate international partnerships that enable Japanese technology, innovations, and insights to play a more direct role in improving global health. Another goal of GHIT is to develop a new drug-discovery screening platform to assist the screening of compound libraries housed within Japanese companies and academic institutions. The vision is to have Japanese research organizations donate compounds, with the Fund reimbursing screening costs and leveraging screening programs of existing product-development partners. | global health, health, drug development, biomarker, consortium, drug, vaccine, diagnostics, healthcare, developing country, disease | is listed by: Consortia-pedia | Government of Japan ; Bill and Melinda Gates Foundation ; Pharmaceutical industry |
grid.475132.6, nlx_157983 | https://ror.org/02yfqyv95 | SCR_003753 | 2026-02-07 02:06:06 | 16 | |||||||
|
Coca-Cola Company Resource Report Resource Website 1+ mentions |
Coca-Cola Company (RRID:SCR_003749) | Coca-Cola, KO | commercial organization | An American multinational beverage corporation and manufacturer, retailer and marketer of nonalcoholic beverage concentrates and syrups, which is headquartered in Atlanta, Georgia. (Wikipedia) It is the world's largest beverage company, refreshing consumers with more than 500 sparkling and still brands. | beverage | Crossref funder ID: 100004367, ISNI: 0000 0004 0504 2170, grid.451378.c, Wikidata: Q3295867, nlx_158091 | https://ror.org/00yc8qw13 | SCR_003749 | KO, The Coca-Cola Company, Coca-Cola | 2026-02-07 02:06:08 | 2 | ||||||||
|
Seven Hills Bioreagents Resource Report Resource Website 1+ mentions |
Seven Hills Bioreagents (RRID:SCR_003748) | commercial organization | An Antibody supplier | nlx_152458 | SCR_003748 | 2026-02-07 02:06:26 | 3 | ||||||||||||
|
RevMan Resource Report Resource Website 10000+ mentions |
RevMan (RRID:SCR_003581) | RevMan | software resource | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 5, 2023.A software package that does meta-analysis and provides results in tabular format and graphically., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. |
is listed by: OMICtools is listed by: SoftCite |
THIS RESOURCE IS NO LONGER IN SERVICE | OMICS_00244 | SCR_003581 | Review Manager | 2026-02-07 02:06:23 | 12959 | ||||||||
|
Torrey Pines Biolabs Resource Report Resource Website 100+ mentions |
Torrey Pines Biolabs (RRID:SCR_003580) | commercial organization | An Antibody supplier | nlx_152481 | SCR_003580 | Torrey Pines Biolabs Inc., Torrey Pines Biolabs Inc | 2026-02-07 02:06:04 | 376 | |||||||||||
|
Charles Stark Draper Laboratory Resource Report Resource Website 1+ mentions |
Charles Stark Draper Laboratory (RRID:SCR_003736) | Draper | nonprofit organization | A not-for-profit research and development laboratory focused on the design, development, and deployment of advanced technological solutions for the nation's most challenging and important problems in security, space exploration, healthcare, and energy. Their expertise includes the areas of guidance, navigation, and control systems; fault-tolerant computing; advanced algorithms and software solutions; modeling and simulation; and MEMS and multichip module technology. With a strong commitment to delivering working solutions to their sponsors, they apply their expertise to a variety of domains, including autonomous air, land, sea, and space systems; information integration; distributed sensors and networks; precision-guided munitions; and biomedical engineering; chemical/biological defense; and energy system modeling and management. When appropriate for the needs of their sponsors, they will work with commercial partners to transition their technology to commercial production. | engineering, technology, research, defense, space, biomedical, energy, service |
is related to: Massachusetts Institute of Technology; Massachusetts; USA; is parent organization of: Center for Integration of Medicine and Innovative Technology |
Acknowledgement required, Non-commercial | grid.417533.7, Crossref funder ID: 100006353, nlx_157942, ISNI: 0000 0004 0634 6125, Wikidata: Q2876029 | https://ror.org/04378d909 | SCR_003736 | Draper Laboratory, The Charles Stark Draper Laboratory Inc | 2026-02-07 02:06:06 | 1 | ||||||
|
PyroBayes Resource Report Resource Website 1+ mentions |
PyroBayes (RRID:SCR_003757) | PyroBayes | software resource | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 6, 2023. A base caller for pyrosequences from the 454 Life Sciences sequencing machines. | is listed by: OMICtools | PMID:18193056 | THIS RESOURCE IS NO LONGER IN SERVICE | OMICS_01155 | SCR_003757 | 2026-02-07 02:06:26 | 3 | ||||||||
|
Oxford Nanopore Technologies Resource Report Resource Website 100+ mentions |
Oxford Nanopore Technologies (RRID:SCR_003756) | Oxford Nanopore | commercial organization | Commercial organization developing a disruptive, proprietary technology platform for the direct, electronic analysis of single molecules. The instruments GridION and MinION are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule. Consequently, the platform has a broad range of potential applications, including scientific research, personalized medicine, crop science and security / defence. | nanopore technology, dna, rna, protein, small molecule, molecule, analysis, nanopore, nanopore sensing |
is related to: READNA is related to: Pychopper |
nlx_158233 | SCR_003756 | Oxford Nanopore Technologies Ltd | 2026-02-07 02:06:06 | 399 | ||||||||
|
Brandeis University; Massachusetts; USA Resource Report Resource Website |
Brandeis University; Massachusetts; USA (RRID:SCR_003669) | university | Private research university located in the Boston suburb of Waltham, Massachusetts. Founded in 1948 as a non-sectarian, coeducational institution sponsored by the Jewish community, Brandeis was established on the site of the former Middlesex University. |
is parent organization of: Paper Rejection Repository is parent organization of: Enhancer Trap Line Browser is parent organization of: Brandeis University Neuroscience Undergraduate Program is parent organization of: Brandeis University Neuroscience Graduate Program is parent organization of: Research Network in Early Experience and Brain Development is parent organization of: Neurofitter is parent organization of: Brandeis University Light Microscopy Core Facility is parent organization of: Brandeis University Louise Mashal Gabbay Cellular Visualization Center Electron Microscopy Core Facility |
nlx_50198, Wikidata:Q49119, ISNI:0000 0004 1936 9473, grid.253264.4, Crossref funder ID:100007864 | https://ror.org/05abbep66 | SCR_003669 | 2026-02-07 02:06:06 | 0 | ||||||||||
|
eBioscience Resource Report Resource Website 50+ mentions |
eBioscience (RRID:SCR_003660) | commercial organization | An Antibody supplier | nlx_152349 | SCR_003660 | 2026-02-07 02:06:05 | 68 | ||||||||||||
|
Signalway Resource Report Resource Website 10+ mentions |
Signalway (RRID:SCR_003659) | SAB | commercial organization | An Antibody supplier | nlx_152462 | SCR_003659 | Signalway Antibody Co. Ltd | 2026-02-07 02:06:06 | 11 | ||||||||||
|
RAREMETAL Resource Report Resource Website 10+ mentions |
RAREMETAL (RRID:SCR_003573) | RAREMETAL | software resource | A software program that facilitates the meta-analysis of rare variants from genotype arrays or sequencing. | bio.tools |
is listed by: OMICtools is listed by: bio.tools is listed by: Debian has parent organization: University of Michigan; Ann Arbor; USA |
PMID:24894501 | biotools:raremetal, OMICS_00243 | https://bio.tools/raremetal | SCR_003573 | 2026-02-07 02:06:05 | 22 | |||||||
|
Corpus Callosum Thickness Profile Analysis Pipeline Resource Report Resource Website |
Corpus Callosum Thickness Profile Analysis Pipeline (RRID:SCR_003575) | ccsegthickness | software resource | An end-to-end pipeline for corpus callosum processing that provides automated midsagittal alignment, CC segmentation with a quality control tool, and thickness profile generation. Groupwise analysis is facilitated by permutation testing with FWER and FDR multiple comparison correction. Results display is facilitated by a display script that shows p-values on a 3D pipe representation of a CC. This pipeline is implemented in MATLAB and requires the Image Processing Toolbox. There are plans to implement it completely in Python. | linux, matlab, mr, nifti-1, posix/unix-like, corpus callosum | is listed by: NeuroImaging Tools and Resources Collaboratory (NITRC) | PMID:24968872 | GNU General Public License | nlx_157716 | SCR_003575 | 2026-02-07 02:06:23 | 0 | |||||||
|
Myelin Repair Foundation Resource Report Resource Website 1+ mentions |
Myelin Repair Foundation (RRID:SCR_003723) | MRF | institution | A non-profit foundation that funds basic research and is focused on accelerating the development of myelin repair therapeutics for multiple sclerosis. They have defined a 15-year research plan to develop a drug or drugs and believes its Accelerated Research Collaborative (ARC) model can subsequently be used to accelerate the treatment for all diseases. The ARC framework coordinates and manages the entire therapeutic development continuum from discovery biology to FDA approval. The model works by coordinating multi-disciplinary basic research from academic and government laboratories, systematically validating and derisking potential compounds/targets, and collaborating with pharma partners to increase the probability of successful programs. | consortium, drug, myelin repair, therapeutic, myelin, drug development | is listed by: Consortia-pedia | Multiple Sclerosis, Neurological disease | nlx_157901, grid.429475.9, Wikidata: Q6947290 | https://ror.org/05yb6xa82 | SCR_003723 | 2026-02-07 02:06:06 | 3 | |||||||
|
Tocris Bioscience Resource Report Resource Website 100+ mentions |
Tocris Bioscience (RRID:SCR_003689) | commercial organization | An Antibody supplier | nlx_152479 | SCR_003689 | 2026-02-07 02:06:07 | 384 | ||||||||||||
|
TransCelerate BioPharma Resource Report Resource Website 1+ mentions |
TransCelerate BioPharma (RRID:SCR_003728) | TransCelerate | nonprofit organization | Non-profit research organization aiming to accelerate drug development by increasing the quality and efficiency of clinical studies through the development of shared tools, methods, and platforms. Consortium partnerships are limited to pharmaceutical and biotechnology companies with research & development operations, although there are collaborations with external organizations such the Clinical Data Interchange Standards Consortium (CDISC). Its current focus is to collaborate on: * Standardizing risk-based monitoring * Development of methods to qualify and train clinical trial sites * Development of a common investigator web portal * Development of clinical data standards on efficacy, and methods for comparator drug trials It currently has 5 projects: # Standardized Approach for High-Quality, Risk-Based Monitoring program aims to develop an industry-wide standard and approach for risk-based monitoring of clinical trials in order to enhance patient safety and ensure the quality of clinical trial data. # Shared Site Qualification and Training program aims to standardize GCP training and site qualification credentials in order to realize efficiencies and accelerate study start-up timelines. # Common Investigator Site Portal is a platform designed to streamline investigator and site access through harmonized delivery of content and services. # Data Standards project is a partnership with CDISC to develop industry-wide data standards in priority therapeutic areas to support the exchange and submission of clinical research and meta-data, improving patient safety and outcomes. # Comparator Drugs project aims to establish reliable, rapid sourcing of quality products for use in clinical trials through a comparator supply model enabling accelerated trial timelines and enhanced patient safety. | drug, clinical trial, multipharma, data sharing, drug development, consortium, medicine, clinical, standard specification | is listed by: Consortia-pedia | Member companies financial contributions ; Member companies in-kind contributions ; GlaxoSmithKline |
nlx_157913 | SCR_003728 | TransCelerate BioPharma Inc. | 2026-02-07 02:06:07 | 4 | |||||||
|
Philips Research Resource Report Resource Website |
Philips Research (RRID:SCR_003871) | commercial organization | A global organization that helps Philips introduce innovations that improve people's lives by providing technology options for innovations in the area of health and well-being, targeted at both developed and emerging markets. Positioned at the front-end of the innovation process, they work on everything from spotting trends and ideation to proof of concept and - where needed - first-of-a-kind product development. | health, well-being, technology |
is related to: READNA has parent organization: Philips |
nlx_158235 | SCR_003871 | 2026-02-07 02:06:09 | 0 | ||||||||||
|
Roslin Cells Resource Report Resource Website 1+ mentions |
Roslin Cells (RRID:SCR_003857) | Roslin Cells | commercial organization | Organization that supplies undifferentiated, clinical grade, human pluripotent stem cell lines to the life science community, and works with academic, clinical and commercial colleagues to enable and facilitate the use of these high grade cells in the development of new reagents, drugs and cellular therapeutics. They also seek to drive the economic development of the stem cell sector in Scotland. Their products can act as a valuable tool in supporting clients' drug discovery, development and clinical research programmes. | pluripotent stem cell, induced pluripotent stem cell, cell therapy, embryonic stem cell line, clinical grade |
is listed by: One Mind Biospecimen Bank Listing is parent organization of: EBiSC |
nlx_158181 | SCR_003857 | Roslin Cells Ltd | 2026-02-07 02:06:29 | 2 | ||||||||
|
PEAR Resource Report Resource Website 500+ mentions |
PEAR (RRID:SCR_003776) | PEAR | software resource | Software for an ultrafast, memory-efficient and highly accurate pair-end read merger. It is fully parallelized and can run with as low as just a few kilobytes of memory. | next-generation sequencing, sequence analysis |
is listed by: OMICtools has parent organization: Heidelberg Institute for Theoretical Studies; Heidelberg; Germany |
PMID:24142950 | OMICS_00674 | SCR_003776 | Pair-end read merger, PEAR: Pair-end read merger | 2026-02-07 02:06:26 | 839 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
